Emerald Mutual Fund Advisers Trust’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-107
Closed -$112K 233
2024
Q3
$112K Hold
107
0.01% 216
2024
Q2
$112K Sell
107
-50
-32% -$48.5K 0.01% 210
2024
Q1
$151K Sell
157
-5
-3% -$4.75K 0.01% 203
2023
Q4
$142K Buy
162
+22
+16% +$18.1K 0.01% 227
2023
Q3
$115K Buy
140
+52
+59% +$40.9K 0.01% 217
2023
Q2
$63.2K Buy
+88
New +$67.8K ﹤0.01% 237
2020
Q4
Sell
-153
Closed -$86K 314
2020
Q3
$86K Buy
+153
New +$92.8K ﹤0.01% 262

Other funds holding REGN

Emerald Mutual Fund Advisers Trust's REGN Position: Q4 2024 in Review

Emerald Mutual Fund Advisers Trust sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 107 shares — an estimated $112K sold.

Emerald Mutual Fund Advisers Trust first reported a position in REGN in Q3 2020 and held it in 7 quarters. The position peaked at $151K in Q1 2024. 1,317 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

  • Emerald Mutual Fund Advisers Trust reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Emerald Mutual Fund Advisers Trust sold 107 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $112K.
  • Emerald Mutual Fund Advisers Trust first reported a position in Regeneron Pharmaceuticals in Q3 2020 and held it in 7 quarters.
  • Emerald Mutual Fund Advisers Trust's Regeneron Pharmaceuticals position peaked at $151K in Q1 2024.
  • 1,317 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on Emerald Mutual Fund Advisers Trust's 13F filing for Q4 2024, filed 14 Feb 2025.